Healthcare & FDA
The latest in healthcare & fda for medical-aesthetics practice owners.
Healthcare & FDA
Simparica Trio Gets Screwworm EUA—Zoetis Wins
FDA emergency authorization for parasitic treatment expands Zoetis' veterinary portfolio.
Healthcare & FDA
FDA Clears Screwworm Prevention Drug for U.S. Livestock
Emergency authorization for CLiK Extra opens market for wound-care products in agriculture.
Healthcare & FDA
FDA Updates Fresh-Cut Produce Safety Guidance
New standards tighten biological hazard controls for manufacturers.
Healthcare & FDA
FDA Approves Tudriqev for Advanced Melanoma
Engineered viral therapy opens door for biotech makers and combination-drug players.
Healthcare & FDA
FTC Sues Hims & Hers Over Privacy and Billing Practices
Telehealth giant faces enforcement action over data handling and customer charges.
Healthcare & FDA
CMS Raises IRF Payments for 2027—Rehab Hospitals Get Relief
Medicare payment boost and rural adjustment phase-out reshape inpatient rehab economics.
Healthcare & FDA
CMS Ends Medicare Part D Subsidy—Drug Plan Insurers Face Margin Pressure
Trump administration cuts retiree premium support; UnitedHealth, Humana, Anthem margins tighten.
Healthcare & FDA
HHS Boosts Hospital Payments by $2 Billion—Acute Care Operators Win
Medicare payment increase flows to hospital operators; staffing and supply chain vendors benefit.
Healthcare & FDA
Humana Exits MA Markets—600K Members Face Plan Disruption
Insurer's pullback signals margin pressure in Medicare Advantage; competitors gain enrollment but face higher costs.
Healthcare & FDA
FDA Revokes Petroleum-Based Food Dyes—Natural Color Makers Win
Orange B and Citrus Red No. 2 face removal from food supply, opening market share for natural and synthetic alternatives.
Healthcare & FDA
CMS Stars Redo Lifts Medicare Advantage Insurers—Rating System Overhaul Favors UnitedHealth, Humana, Anthem
Medicare Advantage rating changes improve insurer scores and reduce quality penalties, boosting earnings for major carriers.
Healthcare & FDA
CMS Overhauls Medicare Advantage Star Ratings—Big Insurers Win, Quality Metrics Tighten
Star-rating changes favor large MA insurers; smaller plans and quality-focused competitors face pressure.
Healthcare & FDA
CMS Overhauls Medicare Advantage Star Ratings—UnitedHealth, Humana, and Anthem Positioned to Gain from Simplified Metrics
CMS stars redo lifts big Medicare Advantage insurers; simplified quality metrics reduce compliance burden and improve bonus payouts.
Healthcare & FDA
CMS's Star Ratings Overhaul Rescues the Biggest Medicare Advantage Insurers — For Now
A methodology reset lifts quality bonus payments for UnitedHealth, Humana, and CVS Health at a moment when all three badly needed the relief.
Healthcare & FDA
CMS Freezes $1 Billion in Medicaid Payments to California and Minnesota — Managed Care Insurers Face Revenue Gaps
HHS's suspension of Medicaid dollars to two large states creates immediate cash flow risk for the managed care organizations that administer those programs.
Healthcare & FDA
CMS's Site-Neutral and 340B Reform Proposal Squeezes Hospital Margins and Lifts Independent Pharmacies
Cutting the payment gap between hospital outpatient departments and doctor's offices hits the hospital REITs and big health systems hardest.
Healthcare & FDA
CMS's Site-Neutral and 340B Cuts Would Squeeze Hospital Systems and Hand Wins to Outpatient Rivals
A proposed CMS rule targeting hospital payment premiums and 340B drug discounts puts large health systems on defense.
Healthcare & FDA
CMS's Proposed 340B Payment Cuts Would Squeeze Hospital Revenue While Helping PBM Rivals
A federal proposal to cut what Medicare pays hospitals under the 340B drug discount program hits hospital systems hardest — and the FTC's Caremark settlement adds pressure on the other side.
Healthcare & FDA
HHS Fraud Crackdown on Medicare Advantage Puts Managed Care Insurers and For-Profit Hospitals on Defense
Federal investigators targeting Medicare Advantage billing fraud create direct earnings risk for insurers and hospital chains with the highest MA exposure.
Healthcare & FDA
FDA Clears Casgevy for Toddlers with Sickle Cell — Vertex and CRISPR Therapeutics Get a Bigger Market
Expanding the approved age to 2-year-olds more than doubles the addressable patient pool for the world's first CRISPR gene therapy.
Healthcare & FDA
Medicare Advantage Plans Are Set to Collect $13 Billion in Quality Bonuses — UnitedHealth and Humana Lead the Queue
CMS quality bonus payments reward the largest MA operators disproportionately, and the 2026 cycle is the biggest payout on record.
Healthcare & FDA
Trump's Proposed Medicare Drug Savings Rule Puts PBMs in the Crosshairs — and Gives Pharma a Mixed Signal
A rule designed to save Medicare patients $1.1 billion on drugs restructures the flow of money between manufacturers, middlemen, and patients.
Healthcare & FDA
FDA Clears Casgevy for Toddlers — Vertex and CRISPR Therapeutics Just Doubled Their Addressable Market
Expanding the gene therapy's label to patients as young as 2 opens a new revenue layer for both companies.
Healthcare & FDA
Medicare Starts Covering Obesity Drugs — Novo Nordisk and Eli Lilly Just Got 67 Million New Potential Customers
CMS coverage of GLP-1s for obesity is the single largest demand expansion in the history of the drug class.
Healthcare & FDA
FDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Get a Bigger Market
The label expansion for the first CRISPR gene therapy now covers pediatric sickle cell patients, widening the addressable pool for a $2M-plus treatment.
Healthcare & FDA
Medicare Covering Obesity Drugs for the First Time Is a Direct Volume Catalyst for Novo Nordisk and Eli Lilly
Millions of Medicare beneficiaries now have a path to GLP-1 coverage — the addressable market for Wegovy and Zepbound just got structurally larger.
Healthcare & FDA
Elevance Suing CMS Over Medicare Advantage Stars Is a Warning Sign for the Entire Managed Care Sector
When the second-largest insurer sues its biggest customer over payment methodology, the sector's regulatory relationship with CMS has deteriorated to a new low.
Healthcare & FDA
Medicare Starts Covering GLP-1 Obesity Drugs — Novo Nordisk and Eli Lilly Are the Direct Winners
For the first time, Medicare will reimburse weight-loss drugs, opening a market of millions of seniors who couldn't previously afford Ozempic or Zepbound.
Healthcare & FDA
FDA Clears Casgevy for Toddlers with Sickle Cell — Vertex and CRISPR Therapeutics Get a Bigger Market
Expanding the approved age to 2 years old roughly doubles the addressable patient pool for the only CRISPR-based gene therapy on the market.
Healthcare & FDA
FDA Expands Casgevy to Children as Young as 2, Widening the Market for Vertex and CRISPR Therapeutics
Lowering the approved age for the first CRISPR gene therapy from 12 to 2 years old meaningfully expands the addressable patient population — and the revenue runway.
Healthcare & FDA
FDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Get a Bigger Market
Lowering the age threshold for the first CRISPR gene therapy meaningfully expands the addressable patient pool for both companies.
Healthcare & FDA
FDA's BHT and ADA Reassessment Puts Food Additive Users on Notice — and Creates an Opening for Clean-Label Suppliers
A formal safety review of two widely used food additives is the kind of regulatory uncertainty that reshuffles ingredient supply chains.
Healthcare & FDA
Medicare Is Now Covering Wegovy — Novo Nordisk and Eli Lilly Just Got a Massive New Payer
The Medicare GLP-1 bridge program opens the largest single payer in the U.S. to obesity drug coverage, and the revenue math is significant.
Healthcare & FDA
FDA Expands Casgevy to Toddlers — Vertex and CRISPR Therapeutics Just Got a Bigger Market
Lowering the approved age for the first CRISPR gene therapy from 12 to 2 years old meaningfully expands the addressable patient pool.
Healthcare & FDA
Medicare Starts Covering GLP-1 Weight-Loss Drugs July 1 — Novo Nordisk and Eli Lilly Just Got 67 Million New Potential Customers
Federal coverage of Wegovy and similar drugs through Medicare is the single largest demand expansion in the GLP-1 market's history.
Healthcare & FDA
FDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Just Got a Bigger Market
Lowering the age threshold for the first CRISPR gene therapy meaningfully expands the addressable patient pool.
Free: catalyst alerts, straight to your inbox.
Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.